IP Library › Granted Patent US 12,280,096
Granted Patent B2
US 12,280,096 · App. 17/862,269 · Granted Apr 22, 2025

Treatments of cancer using nitrous oxide and botulinum toxin

Inventor: Roland M. Williams (Beaumont, TX)
Assignee: Penland Foundation
A61K38/4893A61K9/0021A61K31/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,280,096
App. No.
17/862,269
Granted
Apr 22, 2025
Kind
B2
Abstract

Embodiments of the disclosure are related to a method of treating cancer including preventative treatment comprising administering nitrous oxide and oxygen to the patient by inhalation, and/or administering a botulinum toxin to the patient by injection, wherein the latter is directed to preventative treatment.

Claims (10)

1. A method of treating cancer and/or post-cancer symptoms or conditions in a patient in need thereof, wherein the patient has a physiological state comprising overproduction of substance P and/or glutamate and related cytokine overproduction protecting malignant cancer cells, the method comprising:

administering nitrous oxide and oxygen to the patient by inhalation, thereby treating the cancer and/or post-cancer treatment symptoms or conditions,

wherein when administered to an adult who weighs about 150 lbs., the nitrous oxide and oxygen are administered for about between 1 minute and about 1 hour every about 4-6 hours; or for about 20 minutes every about 4-6 hours; and

providing the patient with cancer treatment.

2. The method of claim 1 , wherein the nitrous oxide and oxygen comprises from about 1% nitrous oxide/about 99% oxygen to about 70% nitrous oxide/about 30% oxygen; from about 40% nitrous oxide/about 60% oxygen to about 50% nitrous oxide/about 50% oxygen; or about 50% nitrous oxide/about 50% oxygen.

3. The method of claim 1 , wherein the nitrous oxide and oxygen are administered by continuous administration over the period of time of 1 minute and about 1 hour.

4. The method of claim 1 , wherein a composition, duration, an interval, and a total amount of the nitrous oxide and oxygen provided to an adult or a child is adjusted for age, weight, or a combination thereof.

5. The method of claim 4 , the cancer treatment comprises one or more of the following: surgery, chemotherapy, radiation, programmed immune cells, and antibodies.

6. The method of claim 4 , the method further comprising monitoring glutamate and Substance P suppression and in response, modifying the administration of nitrous oxide and oxygen by inhalation.

7. The method of claim 4 , the method further comprising administering folic acid to the patient.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 19, 2022
From: WILLIAMS, ROLAND M.
To: PENLAND FOUNDATION
Reel/Frame 060546/0187 →
Continuity (2)
Provisional Application 63220951 · Jul 12, 2021
Related Publication 20230009875A1 · Jan 12, 2023
References Cited (108)
US 6063768A · First · 2000 [cited by applicant]
US 6500436B2 · Donovan · 2002 [cited by applicant]
US 7235584B2 · Garzon et al. · 2007 [cited by applicant]
US 8372976B2 · Mortensen et al. · 2013 [cited by applicant]
US 8399401B2 · Foster et al. · 2013 [cited by applicant]
US 8697066B2 · Gaylis et al. · 2014 [cited by applicant]
US 9243301B2 · Foster et al. · 2016 [cited by applicant]
US 9579299B2 · Glozman · 2017 [cited by applicant]
US 9945856B2 · Van Der Hoek · 2018 [cited by applicant]
US 10064921B2 · Blumenfeld · 2018 [cited by applicant]
US 10201565B2 · Mailova et al. · 2019 [cited by applicant]
US 10245305B2 · First · 2019 [cited by applicant]
US 10857382B2 · Ibrahim et al. · 2020 [cited by applicant]
US 11065218B2 · Bannister et al. · 2021 [cited by applicant]
US 20020185126A1 · Krebs · 2002 [cited by applicant]
US 20050020654A1 · Pershadsingh et al. · 2005 [cited by applicant]
US 20050152905A1 · Omoigui · 2005 [cited by applicant]
US 20050267009A1 · Deagle · 2005 [cited by applicant]
US 20060178354A1 · Lucas · 2006 [cited by applicant]
US 20090071481A1 · Fishman · 2009 [cited by applicant]
US 20090232849A1 · Gallez et al. · 2009 [cited by applicant]
US 20090324678A1 · Thorne et al. · 2009 [cited by applicant]
US 20120207733A1 · Jacky et al. · 2012 [cited by applicant]
US 20120207742A1 · Jacky et al. · 2012 [cited by applicant]
US 20130095194A1 · Bessiere et al. · 2013 [cited by applicant]
US 20130177548A1 · Shaari · 2013 [cited by applicant]
US 20130302445A1 · Barbut et al. · 2013 [cited by applicant]
US 20150197739A1 · James et al. · 2015 [cited by applicant]
US 20160067276A1 · Polizzotti et al. · 2016 [cited by applicant]
US 20160243232A1 · Pickett · 2016 [cited by applicant]
US 20170049866A1 · Sanders · 2017 [cited by applicant]
US 20170136105A1 · Ho et al. · 2017 [cited by applicant]
US 20170246267A1 · Wang et al. · 2017 [cited by applicant]
US 20180235931A1 · Basta et al. · 2018 [cited by applicant]
US 20180243373A1 · Hamed · 2018 [cited by applicant]
US 20180296582A1 · Von Maltzahn et al. · 2018 [cited by applicant]
US 20180296732A1 · Kutryk · 2018 [cited by applicant]
US 20190127718A1 · Madec et al. · 2019 [cited by applicant]
US 20190185837A1 · Jacky et al. · 2019 [cited by applicant]
US 20190298779A1 · Falb et al. · 2019 [cited by applicant]
US 20190314470A1 · Khavari et al. · 2019 [cited by applicant]
US 20190315836A1 · Delahay · 2019 [cited by applicant]
US 20200046813A1 · Borodic · 2020 [cited by applicant]
US 20200056145A1 · Brown et al. · 2020 [cited by applicant]
US 20200360483A1 · Dong et al. · 2020 [cited by applicant]
US 20200368365A1 · Ruoslahti et al. · 2020 [cited by applicant]
US 20210121541A1 · Brin et al. · 2021 [cited by applicant]
US 20210130445A1 · Brin · 2021 [cited by applicant]
US 20210177823A1 · Weinstein et al. · 2021 [cited by applicant]
US 20210177946A1 · Sanders · 2021 [cited by applicant]
US 20210205415A1 · Shandler et al. · 2021 [cited by applicant]
US 20210205422A1 · Kalinichev et al. · 2021 [cited by applicant]
US 20210252033A1 · Painter et al. · 2021 [cited by applicant]
AU 2011203062 · 2013 [cited by applicant]
CN 101031317 · 2012 [cited by applicant]
CN 105147608 · 2015 [cited by applicant]
EP 1187635 · 2004 [cited by applicant]
EP 1807118 · 2007 [cited by applicant]
EP 1890714 · 2008 [cited by applicant]
EP 1919892 · 2008 [cited by applicant]
EP 2012811 · 2009 [cited by applicant]
EP 2200999 · 2010 [cited by applicant]
EP 2610244 · 2013 [cited by applicant]
EP 2279196 · 2015 [cited by applicant]
EP 2985281 · 2016 [cited by applicant]
EP 2667854 · 2019 [cited by applicant]
EP 3689331 · 2020 [cited by applicant]
KR 20170014106 · 2017 [cited by applicant]
WO 0155304 · 2001 [cited by applicant]
WO 0276177 · 2002 [cited by applicant]
WO 2005009437 · 2005 [cited by applicant]
WO 2006018655 · 2006 [cited by applicant]
WO 2008064552 · 2008 [cited by applicant]
WO 2014053651 · 2014 [cited by applicant]
WO 2018129404 · 2018 [cited by applicant]
WO 2019051380 · 2019 [cited by applicant]
WO 2019075263 · 2019 [cited by applicant]
WO 2019191752 · 2019 [cited by applicant]
WO 2020010123 · 2020 [cited by applicant]
WO 2020065249 · 2020 [cited by applicant]
WO 2020117564 · 2020 [cited by applicant]
WO 2020218823 · 2020 [cited by applicant]
WO 2021101902 · 2021 [cited by applicant]
WO 2021113311 · 2021 [cited by applicant]
WO 2021163222 · 2021 [cited by applicant]
Jung et al. (Korean Journal of Anesthesiology vol. 58 No. 1, pp. 61-69). [cited by examiner]
Koblin (Seminars in Surgical Oncology vol. 6 No. 3, pp. 141-147). [cited by examiner]
Lassen and Kristensen, “Remission in Chronic Myeloid Leucemia Following Prolonged Nitrous Oxide Inhalation,” Danish Medical Bulletin, vol. 6, No. 8, pp. 252-255 (1959). [cited by applicant]
Aguirre-Siancas, “Substance p. proinflammatory cytokines, transient receptor potential vanilloid subtype 1 and COVID-19: a working hypothesis,” Neurología, 36, pp. 169-189 (2021). [cited by applicant]
Australian Dental Association, “The Use of Nitrous Oxide During COVID-19,” available online at <https://www.ada.org.au/Covid-19-Portal/Cards/Misc/Infection-Control-Cards/The-Use-of-Nitrous-Oxide-During-COVID-19>, 2 page… [cited by applicant]
Fleischmann, “Nitrous oxide may not increase the risk of cancer recurrence after colorectal surgery: a follow-up of a randomized controlled trial,” BMC Anesthesiology, (2009). [cited by applicant]
International Search Report and Written Opinion for International Patent Application No. PCT/US2022/036729, mailed Nov. 15, 2022 (12 pages). [cited by applicant]
Ishikawa, “Nitrous Oxide Decreases Substance p. Receptor Binding in The Rat Spinal Cord,” Journal of Neurosurgical Anesthesiology, 1(4), pp. 316-322 (1989). [cited by applicant]
Turan et al., “Nitrous Oxide for the Treatment of Chronic Low Back Pain,” Anesthesia & Analgesia, 121(5), pp. 1350-1359 (2015). [cited by applicant]
Lichtigfeld et al., “The treatment of alcoholic withdrawal states with oxygen and nitrous oxide,” South African Medical Journal, 61(349), pp. 349-351 (1982). [cited by applicant]
Lotz et al., “Effects of inhaled nitric oxide in COVID-19-induced ARDS—Is it worthwhile?” Acta Anaesthesiol. Scand., 65, pp. 629-632 (2021). [cited by applicant]
Manigandan et al., “A review on role of nitrous oxide nanoparticles, potential vaccine targets, drug, health care and artificial intelligence to combat COVID-19,” Applied Nanoscience, 8 pages (2021). [cited by applicant]
Mehboob, “Aprepitant as a combinant with Dexamethasone reduces the inflammation via Neurokinin 1 Receptor Antagonism in severe to critical Covid-19 patients and potentiates respiratory recovery: A novel therapeutic appr… [cited by applicant]
Miller et al., “Inhalational Anesthetic,” StatPearls Publishing, Treasure Island (FL); 10 pages (2021). [cited by applicant]
Wiley, “Use of nitrous oxide- oxygen inhalation sedation in the COVID- 19 era,” Int. J. Paediatr. Dent., 31, pp. 433-435 (2021). [cited by applicant]
Molina et al., “Nitrous oxide inhalant abuse and massive pulmonary embolism in COVID-19,” American Journal of Emergency Medicine, 38(7), 2 pages. 1549.e1-1549.e2 (2020). [cited by applicant]
National Cancer Institute, “Cancer Pain (PDQ®)-Health Professional Version,” available online at <https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq>; Updated Sep. 2, 2022, 89 pages. [cited by applicant]
National Cancer Institute, “Nitric Oxide Releasing Solutions to Prevent and Treat Mild/Moderate COVID-19 Infection (NOCOVID),” available online at <https://clinicaltrials.gov/ct2/show/NCT04337918>; First Posted: Apr. 8,… [cited by applicant]
Nowaczyk et al., “Carbon Monoxide and Nitric Oxide as Examples of the Youngest Class of Transmitters,” Int. J. Mol. Sci., 22(6029), 25 pages (2021). [cited by applicant]
Park et al., “Cytokine Balance in the Lungs of Patients with Acute Respiratory Distress Syndrome,” American Journal of Respiratory and Critical Care Medicine, 164(10), pp. 1896-1903 (2011). [cited by applicant]
Patyar et al., “Bacteria in cancer therapy: a novel experimental strategy,” Journal of Biomedical Science vol. 17 (21), 9 pages (2010). [cited by applicant]
Rao et al., “Comparison of five equations for estimating resting energy expenditure in Chinese young, normal weight healthy adults,” European Journal of Medical Research, 17(26), pp. 1-9 (2012). [cited by applicant]
Takasusuki et al., “Effects of General Anesthetics on Substance P Release and c-Fos Expression in the Spinal Dorsal Horn,” Anesthesiology, 119, pp. 433-442 (2013). [cited by applicant]